Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation (GKOS) filed a Form 144 reporting a proposed sale of 5,142 common shares, acquired through restricted stock vesting as compensation during March–July 2024. The filing lists an aggregate market value of $453,607.98 for the shares and reports 57,349,987 shares outstanding. The proposed sale date is 09/11/2025 and the broker is listed as Fidelity Brokerage Services LLC on the NYSE. The filer reports no securities sold during the past three months and attests not to possess undisclosed material information.
Glaukos Corporation filed a Form S-8 registration statement to register additional shares of its common stock for issuance under the Glaukos Corporation 2015 Employee Stock Purchase Plan. This filing uses the abbreviated process under General Instruction E to Form S-8, meaning it builds on earlier registration statements for the same plan.
The company incorporates by reference its previously filed Exchange Act reports, so future SEC filings will automatically update this registration. An opinion on the validity of the common stock being registered is provided by Robert Davis, the company’s Senior Vice President, General Counsel and Business Development. The document also includes standard consents, an exhibit index for the ESPP, and signatures from the CEO, CFO, and all directors authorizing the filing.
Wellington Management reports beneficial ownership of 3,244,404 shares of Glaukos Corporation common stock, representing approximately 5.68% of the class. The filing shows no sole voting or dispositive power; voting power is shared for about 2,833,990 shares while shared dispositive power equals the full 3,244,404 shares disclosed.
The securities are owned of record by clients of Wellington investment advisers and are reported as held in the ordinary course of business on a Schedule 13G. Multiple Wellington entities are listed as reporting persons and two classifications appear: several entities as HC (holding companies) and Wellington Management Company LLP as IA (investment adviser).
Glaukos Corporation disclosed that it will present an investor presentation attached as Exhibit 99.1 to this Current Report and that the presentation will be made available on the company’s investor website. The company states the presentation may be used in investor and stakeholder meetings and that the information in Item 7.01 and Exhibit 99.1 is not intended to be deemed filed under the Exchange Act or incorporated by reference in other filings unless explicitly stated.
The report also lists an interactive cover page data file as Exhibit 104. No financial statements, earnings data, or material transactions are included in this filing.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
